Inhibition of BTK by small-molecule inhibitors showed high efficacy in several preclinical autoimmune models and clinical efficacy was observed for fenebrutinib in RA and evobrutinib in MS [163,164]. This evidence concerns the gene BTK and rheumatoid arthritis.